Back to Search
Start Over
BiTE immuno-oncology therapy appears safe with preliminary efficacy in mCRPC: More than 25% of patients show confirmed PSA response to investigational treatment.
- Source :
-
Urology Times . Nov2020, Vol. 48 Issue 11, p25-25. 1p. - Publication Year :
- 2020
-
Abstract
- The article discusses the research paper "Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)," by Ben Tran, L. Horvath, T. Dorff, et al., which was presented at the 2020 European Society for Medical Oncology Virtual Congress held on September 19-21. Also detailed are the safety and the antitumor activity of AMG 160.
Details
- Language :
- English
- ISSN :
- 00939722
- Volume :
- 48
- Issue :
- 11
- Database :
- Academic Search Index
- Journal :
- Urology Times
- Publication Type :
- Periodical
- Accession number :
- 147099520